151 related articles for article (PubMed ID: 37584290)
1. Isatuximab plus carfilzomib and dexamethasone in patients with early
Facon T; Moreau P; Baker R; Min CK; Leleu X; Mohty M; Karlin L; Armstrong NM; Tekle C; Schwab S; Risse ML; Martin T
Haematologica; 2024 Feb; 109(2):604-616. PubMed ID: 37584290
[TBL] [Abstract][Full Text] [Related]
2. Isatuximab Plus Carfilzomib and Dexamethasone Versus Carfilzomib and Dexamethasone in Patients with Relapsed Multiple Myeloma: IKEMA Subgroup Analysis by Prior Transplantation.
Martin TG; Capra M; Mohty M; Suzuki K; Quach H; Cavo M; Moreau P; Dimopoulos M; Yong K; Tekle C; Foster MC; Barnes Y; Risse ML; Mikhael J
Transplant Cell Ther; 2023 Feb; 29(2):134.e1-134.e7. PubMed ID: 36372355
[TBL] [Abstract][Full Text] [Related]
3. Isatuximab plus carfilzomib and dexamethasone in East Asian patients with relapsed multiple myeloma: IKEMA subgroup analysis.
Kim K; Min CK; Koh Y; Ishizawa K; Kim SH; Ito S; Tanaka J; Uchiyama M; Kawano Y; Kim JS; Moreau P; Martin T; Dong Y; Risse ML; Suzuki K
Int J Hematol; 2022 Oct; 116(4):553-562. PubMed ID: 35578151
[TBL] [Abstract][Full Text] [Related]
4. Depth of response and response kinetics of isatuximab plus carfilzomib and dexamethasone in relapsed multiple myeloma.
Martin T; Mikhael J; Hajek R; Kim K; Suzuki K; Hulin C; Garg M; Quach H; Sia H; George A; Konstantinova T; Risse ML; Asset G; Macé S; van de Velde H; Moreau P
Blood Adv; 2022 Aug; 6(15):4506-4515. PubMed ID: 35594559
[TBL] [Abstract][Full Text] [Related]
5. Isatuximab in combination with carfilzomib and dexamethasone in 1q21+ patients with relapsed/refractory multiple myeloma: Long-term outcomes in the Phase 3 IKEMA study.
Facon T; Moreau P; Špicka I; Suzuki K; Yong K; Mikhael J; Fukao T; Bisht K; Armstrong NM; Macé S; Risse ML; Martin T
Hematol Oncol; 2024 Mar; 42(2):e3258. PubMed ID: 38402467
[TBL] [Abstract][Full Text] [Related]
6. Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in relapsed multiple myeloma patients with renal impairment: IKEMA subgroup analysis.
Capra M; Martin T; Moreau P; Baker R; Pour L; Min CK; Leleu X; Mohty M; Segura MR; Turgut M; LeBlanc R; Risse ML; Malinge L; Schwab S; Dimopoulos M
Haematologica; 2022 Jun; 107(6):1397-1409. PubMed ID: 34647444
[TBL] [Abstract][Full Text] [Related]
7. Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 study.
Martin T; Dimopoulos MA; Mikhael J; Yong K; Capra M; Facon T; Hajek R; Špička I; Baker R; Kim K; Martinez G; Min CK; Pour L; Leleu X; Oriol A; Koh Y; Suzuki K; Casca F; Macé S; Risse ML; Moreau P
Blood Cancer J; 2023 May; 13(1):72. PubMed ID: 37156782
[TBL] [Abstract][Full Text] [Related]
8. Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in elderly patients with relapsed multiple myeloma: IKEMA subgroup analysis.
Facon T; Moreau P; Martin TG; Spicka I; Oriol A; Koh Y; Lim A; Mikala G; Rosiñol L; Yağci M; Cavo M; Yong K; Risse ML; Asset G; Schwab S; Martinez G
Hematol Oncol; 2022 Dec; 40(5):1020-1029. PubMed ID: 35653225
[TBL] [Abstract][Full Text] [Related]
9. Isatuximab Plus Carfilzomib and Dexamethasone in East Asian Patients With Relapsed Multiple Myeloma: Updated IKEMA Subgroup Analysis.
Kawano Y; Kim K; Min CK; Koh Y; Ishizawa K; Kim SH; Ito S; Tanaka J; Uchiyama M; Ishida T; Kim JS; Moreau P; Martin T; Tada K; Risse ML; Suzuki K
Clin Lymphoma Myeloma Leuk; 2023 Oct; 23(10):e360-e367. PubMed ID: 37479547
[TBL] [Abstract][Full Text] [Related]
10. Isatuximab plus carfilzomib and dexamethasone in relapsed multiple myeloma patients with high-risk cytogenetics: IKEMA subgroup analysis.
Spicka I; Moreau P; Martin TG; Facon T; Martinez G; Oriol A; Koh Y; Lim A; Mikala G; Rosiñol L; Yağci M; Cavo M; Risse ML; Asset G; Macé S; van de Velde H; Yong K
Eur J Haematol; 2022 Nov; 109(5):504-512. PubMed ID: 35871357
[TBL] [Abstract][Full Text] [Related]
11. Isatuximab, carfilzomib and dexamethasone (Isa-Kd) for the management of relapsed multiple myeloma.
Banerjee R; Lo M; Martin TG
Future Oncol; 2021 Dec; 17(35):4849-4860. PubMed ID: 34553603
[TBL] [Abstract][Full Text] [Related]
12. Matching-adjusted indirect comparison of isatuximab plus carfilzomib and dexamethasone with daratumumab plus lenalidomide and dexamethasone in relapsed multiple myeloma.
Richter J; Lin PL; Garcia-Horton V; Guyot P; Singh E; Zhou ZY; Sievert M; Taiji R
Cancer Med; 2023 Apr; 12(7):8005-8017. PubMed ID: 36726287
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of isatuximab in patients with soft-tissue plasmacytomas: An analysis from ICARIA-MM and IKEMA.
Beksac M; Spicka I; Hajek R; Bringhen S; Jelínek T; Martin T; Mikala G; Moreau P; Symeonidis A; Rawlings AM; van de Velde H; Richardson PG
Leuk Res; 2022 Nov; 122():106948. PubMed ID: 36108425
[TBL] [Abstract][Full Text] [Related]
14. Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial.
Moreau P; Dimopoulos MA; Mikhael J; Yong K; Capra M; Facon T; Hajek R; Špička I; Baker R; Kim K; Martinez G; Min CK; Pour L; Leleu X; Oriol A; Koh Y; Suzuki K; Risse ML; Asset G; Macé S; Martin T;
Lancet; 2021 Jun; 397(10292):2361-2371. PubMed ID: 34097854
[TBL] [Abstract][Full Text] [Related]
15. Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 study.
Usmani SZ; Quach H; Mateos MV; Landgren O; Leleu X; Siegel D; Weisel K; Gavriatopoulou M; Oriol A; Rabin N; Nooka A; Qi M; Beksac M; Jakubowiak A; Ding B; Zahlten-Kumeli A; Yusuf A; Dimopoulos M
Lancet Oncol; 2022 Jan; 23(1):65-76. PubMed ID: 34871550
[TBL] [Abstract][Full Text] [Related]
16. Carfilzomib in relapsed or refractory multiple myeloma patients with early or late relapse following prior therapy: A subgroup analysis of the randomized phase 3 ASPIRE and ENDEAVOR trials.
Mateos MV; Goldschmidt H; San-Miguel J; Mikhael J; DeCosta L; Zhou L; Obreja M; Blaedel J; Szabo Z; Leleu X
Hematol Oncol; 2018 Apr; 36(2):463-470. PubMed ID: 29446103
[TBL] [Abstract][Full Text] [Related]
17. Daratumumab for patients with myeloma with early or late relapse after initial therapy: subgroup analysis of CASTOR and POLLUX.
Spencer A; Moreau P; Mateos MV; Goldschmidt H; Suzuki K; Levin MD; Sonneveld P; Orlowski RZ; Yoon SS; Usmani SZ; Weisel K; Reece D; Ahmadi T; Pei H; Mayo WG; Gai X; Carey J; Bartlett JB; Carson R; Dimopoulos MA
Blood Adv; 2024 Jan; 8(2):388-398. PubMed ID: 38048391
[TBL] [Abstract][Full Text] [Related]
18. Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study.
Dimopoulos M; Quach H; Mateos MV; Landgren O; Leleu X; Siegel D; Weisel K; Yang H; Klippel Z; Zahlten-Kumeli A; Usmani SZ
Lancet; 2020 Jul; 396(10245):186-197. PubMed ID: 32682484
[TBL] [Abstract][Full Text] [Related]
19. Isatuximab plus carfilzomib/dexamethasone versus carfilzomib/dexamethasone in patients with relapsed/refractory multiple myeloma: IKEMA Phase III study design.
Moreau P; Dimopoulos MA; Yong K; Mikhael J; Risse ML; Asset G; Martin T
Future Oncol; 2020 Jan; 16(2):4347-4358. PubMed ID: 31833394
[TBL] [Abstract][Full Text] [Related]
20. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): follow-up analysis of a randomised, phase 3 study.
Richardson PG; Perrot A; San-Miguel J; Beksac M; Spicka I; Leleu X; Schjesvold F; Moreau P; Dimopoulos MA; Huang JS; Minarik J; Cavo M; Prince HM; Malinge L; Dubin F; van de Velde H; Anderson KC
Lancet Oncol; 2022 Mar; 23(3):416-427. PubMed ID: 35151415
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
